Abstract
In the post-genomic age, the means to search the entire genome for biomarkers has become available, but the conventional approaches to biomarker discovery are entirely inadequate to yield results with the new technology. Finding clinically useful biomarker panels with sensitivity and specificity equal to that of cystoscopy is a problem of systems biology. Biomarkers are capable of bridging the distance between basic research and late-stage clinical trials and can even shorten it. Many pharmaceuticals and biotech companies are investing additional resources to bring biomarkers into the clinic. They hope that these efforts to practice pharmacogenomic research both in the preclinical and clinical stages will increase the odds of finding a successful drug. Most of the biomarker discovery utilize the microarrays for RNA analysis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aebersold, R., Goodlett, D.R., 2001, Mass spectrometry in proteomics. Chem Rev 101:269–295.
Anderson, N.L., Anderson, N.G., 1998, Proteome and proteomics: New technologies, new concepts and new words. Electrophoresis 19:1853–1861.
Atkinson, A.J., 2001, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95.
Bandara, L.R., Kelly, M.D., Lock, E.A., Kennedy, S., 2003, A potential biomarker of kidney damage identified by proteomics: preliminary findings. Biomarkers 8(3–4):272–286.
Caprioli, R.M., Farmer, T.B., Gile, J., 1997, Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 69(23):4751–4760.
Chaurand, P., Schwartz, S.A., Caprioli, R.M., 2004, Profiling and imaging proteins in tissue sections by MS. Anal Chem 76:86A–93A.
Cui, H., Cruz-Correa, M., Giardiello, F.M., Hutcheon, D.F., Kafonek, D.R., Brandenburg, S., Wu, Y., He, X., Powe, N.R., Feinberg, A.P., 2003, Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299(5613):1753–1755.
Dhanasekaran, S.M., Barrette, T.R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K.J., Rubin, M.A., Chinnaiyan, A.M., 2001, Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849):822–826.
Diamandis, E.P., 2004, Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 3:367–378.
Fenn, J.B., Mann, M., Meng, C.K., Wong, S.F., Whitehouse, C.M., 1989, Electrospray ionization for mass spectrometry of large biomolecules. Science 246:64–71.
Ferber, G., 2002, Biomarkers and proof of concept. Methods find. Exp Clin Pharmacol 24:35–40.
Hammond, M.E., Taube, S.E., 2002, Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin Oncol 29:213–221.
Hanash, S., 2003, Harnessing immunity for cancer marker discovery. Nat Biotechnol 21:37–38.
Hurst, R.E., 2009, Does the biomarker search paradigm need re-booting? BMC Urol 9:1.
Issaq, H.J., Veenstra, T.D., Conrads, T.P., Felschow, D., 2002, The SELDI TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 292(3):587–592.
Kennedy, S., 2002, The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers 7:269–290.
MacGregor, J.T., 2003, The future of regulatory toxicology: impact of the biotechnology revolution toxicological. Sciences 75:236–248.
Morrow, D.A., Braunwald, E., 2003, Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 108:250–252.
Negm, R.S., Verma, M., Srivastava, S., 2002, The promise of biomarkers in cancer screening and detection. Trends Mol Med 8:288–293.
Paweletz, C.P., Trock, B., Pennanen, M., Tsangaris, T., Magnant, C., Liotta, L.A., Petricoin, E.F., 2001, Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 17(4):301–307.
Pepe, M.S., Etzioni, R., Feng, Z., Potter, J.D., Thompson, M.L., Thornquist, M., Winget, M., Yasui, Y., 2001, Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14):1054–1061.
Pepe, M.S., Etzioni, R., Feng, Z., Potter, J.D., Thompson, M.L., Thornquist, M., Winget, M., Yasui, Y., 2004, Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res 64(24):9093–9100.
Reyzer, M.L., Caldwell, R.L., Dugger, T.C., et al., 2004, Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res 64:9093–9100.
Shin, B.K., Wang, H., Hanash, S., 2002, Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J Mammary Gland Biol Neoplasia 7:407–413.
Sidransky, D., 2002, Emerging molecular markers of cancer. Nat Rev Cancer 2:210–219; doi:10.1038/nrc755.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Debnath, M., Prasad, G.B., Bisen, P.S. (2010). Biomarkers. In: Molecular Diagnostics: Promises and Possibilities. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-3261-4_18
Download citation
DOI: https://doi.org/10.1007/978-90-481-3261-4_18
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-3260-7
Online ISBN: 978-90-481-3261-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)